Search results
HALO Stock: Halozyme Gets Under Your Skin To Deliver Blockbuster Drugs And Booming Growth
Investor's Business Daily· 2 years agoHalozyme's under-the-skin technology helps deliver some of the biggest moneymaking injections,...
Halozyme (HALO) Q2 Earnings & Revenues Beat, 2023 View Raised
Zacks via Yahoo Finance· 10 months agoHalozyme (HALO) shares rise 4% in the after-market trading hours on better-than-expected...
Halozyme (HALO) Stock Rises 35% in the Year so Far: Here's Why
Zacks via Yahoo Finance· 2 years agoHalozyme (HALO) is gaining on its proprietary drug delivery technology, ENHANZE. It expects strong...
Halozyme (HALO) Q2 Earnings and Sales Beat, Ups '22 Outlook
Zacks via Yahoo Finance· 2 years agoHalozyme's (HALO) second-quarter earnings and sales beat estimates. Following the completion of the...
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q3 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 7 months agoHalozyme Therapeutics, Inc. (NASDAQ:HALO) Q3 2023 Earnings Call Transcript November 6, 2023 Halozyme...
Halozyme Therapeutics (HALO) Expected to Beat Earnings Estimates: Should You Buy?
Zacks via Yahoo Finance· 2 years agoHalozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely...
Halozyme Therapeutics (HALO) Q4 Earnings Match Estimates
Zacks via Yahoo Finance· 3 months agoHalozyme Therapeutics (HALO) delivered earnings and revenue surprises of 0% and 2.22%, respectively,...
Why Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report?
Zacks via Yahoo Finance· 2 months agoA month has gone by since the last earnings report for Halozyme Therapeutics (HALO). Shares have...
Halozyme Therapeutics Inc (HALO) Reports Strong Year-Over-Year Growth in Q4 and Full Year 2023 ...
GuruFocus.com via Yahoo Finance· 3 months agoRevenue Growth: Q4 revenue increased by 27% YOY to $230 million; full year 2023 revenue up 26% YOY...
Halozyme Therapeutics (HALO) Upgraded to Buy: Here's What You Should Know
Zacks via Yahoo Finance· 1 month agoHalozyme Therapeutics (HALO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism...